.1 Acid reflux time: two.8 General reflux episodes: Mixed or liquid reflux episodes: 128 94 General reflux episodes: Mixed or liquid reflux episodes: 143 140 General reflux episodes: Mixed or liquid reflux episodes: 96 79 General reflux episodes: Mixed or liquid reflux episodes: 108Gaseous reflux episodes: 34 Acid reflux episodes: Non- and/or weakly acid reflux episodes: *Scale 0 to 10: 0 = none; ten = unbearable 84Gaseous reflux episodes: three Acid reflux episodes: Non- and/or weakly acid reflux episodes: 15Gaseous reflux episodes: 17 Acid reflux episodes: Non- and/or weakly acid reflux episodes: 17Gaseous reflux episodes: 4 Acid reflux episodes: Non- and/or weakly acid reflux episodes: 71Subjective symptom scores* – Heartburn + Regurgitation: five – Limitation of every day life: 5 SI: optimistic for heartburn and regurgitationSubjective symptom scores* – Heartburn + Regurgitation: 7 – Limitation of every day life: 6 SI: good for heartburn and regurgitationSubjective symptom scores* – Regurgitation: 5 – Limitation of day-to-day life: 5 SI: constructive for regurgitationSubjective symptom scores* – Heartburn, Globus, Bloating: 9 – Limitation of day-to-day life: 9 SI: optimistic for heartburn, globus and bloatingMII multichannel impedance monitoring, SI – symptom index. Subjective symptom score is based on the questionnaire previously described by Becker V et al. [7]. SI, Symptom index.Nennstiel et al. Journal of Healthcare Case Reports 2014, 8:34 http://www.jmedicalcasereports/content/8/1/Page 4 ofTable 3 Benefits of multichannel impedance-pH monitoring during pucalopride-treatment [7]Patient 1 MII and/or pH Medication for the duration of monitoring for the duration of monitoring: therapy with – Pantoprazole 40mg prucalopride every day + Prucalopride 2mg every day Acid reflux time: Patient two Medication in the course of monitoring: – Pantoprazole 40mg every day + Prucalopride 2mg each day 0.1 Acid reflux time: Patient three Medication for the duration of monitoring: – Omeprazole 20mg each day + Prucalopride 2mg per day 0.9 Acid reflux time: 1.two Acid reflux time: General reflux episodes: Mixed or liquid reflux episodes: Gaseous reflux episodes: 1.9 59 40 19 39 Acid reflux episodes: Non- and/ or weakly acid reflux episodes: 20 Patient 4 Medication through monitoring: – Prucalopride 2mg per dayOverall reflux episodes: 46 Mixed or liquid reflux 5 episodes: Gaseous reflux episodes: Acid reflux episodes: Non- and/or weakly acid reflux episodes: *Scale 0 to10: 0 = none; 10 = unbearable 41 17Overall reflux episodes: 108 Mixed or liquid reflux one hundred episodes: Gaseous reflux episodes: Acid reflux episodes: Non- and/or weakly acid reflux episodes: eight 32Overall reflux episodes: 83 Mixed or liquid reflux 74 episodes: Gaseous reflux episodes: Acid reflux episodes: Non- and/or weakly acid reflux episodes: 9 26Subjective symptom scores* Subjective symptom scores* Subjective symptom scores* Subjective symptom scores* – Heartburn + Regurgitation: three – Heartburn + Regurgitation: five – Regurgitation: 3 Limitation of every day life: three SI: good for heartburn and regurgitation Limitation of day-to-day life: 5 SI: constructive for heartburn, adverse for regurgitation Limitation of each day life: three SI: adverse for regurgitation – Heartburn, Globus, Bloating: 4 Limitation of every day life: 9 SI: unfavorable for heartburn, globus and bloatingMII multichannel impedance monitoring, SI symptom index.IL-33 Protein , Human (CHO) Subjective symptom scores are primarily based around the questionnaire previously described by Becker V et al.Merestinib Inhibitor [7].PMID:26446225 SAP, Symptom association probability; SI, Symptom index.PatientThis 40-year-.
